The OJC 56: Is Food the Future of Cancer Treatment?

Pinterest LinkedIn Tumblr +

The Oncology Journal Club Episode 56: Is food the future of cancer treatment? 

Is the future of cancer treatment food? Hans thinks so! This week he presents Nature papers focused on diet.

Eva talks us through breast cancer patients with low hormone receptor positivity. And Craig presents the Dutch PLASTIC study provoking a great discussion around PET scans for staging locally advanced gastric cancer.

You’ll also find out links between immune checkpoint inhibitors and decreased incidence of second primary cancers. And the Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms. And Eva talks us through a great exercise paper from our friend Matthew Katz.

In ‘The Paper That Changed My practice’ segment – we hear from Mark Nalder, a young medical oncologist from Queensland.

This Week’s Main Papers:

  1. Schrodi S, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol. 2021 Nov;32(11):1410-1424. doi: 10.1016/j.annonc.2021.08.1988. Epub 2021 Aug 20. PMID: 34419555. Access online here.
  2. Lien EC, et al. Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 2021 Oct 20. doi: 10.1038/s41586-021-04049-2. Epub ahead of print. PMID: 34671163. Access online here.
  3. Gertsen EC, e tal. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC). JAMA Surg. 2021 Oct 27:e215340. doi: 10.1001/jamasurg.2021.5340. Epub ahead of print. PMID: 34705049. Access online here.

This Week’s Short Bites:

  1. Pomatto-Watson LCD, et al. Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. Nat Commun. 2021 Oct 27;12(1):6201. doi: 10.1038/s41467-021-26431-4. PMID: 34707136; PMCID: PMC8551193. Access online here.
  2. Heudel P, et al. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer. ESMO Open. 2021 Feb;6(1):100044. doi: 10.1016/j.esmoop.2020.100044. Epub 2021 Jan 27. PMID: 33516148; PMCID: PMC7844579. Access online here.
  3. Parker NH, et al. The Role of Home-Based Exercise in Maintaining Skeletal Muscle During Preoperative Pancreatic Cancer Treatment. Integr Cancer Ther. 2021 Jan-Dec;20:1534735420986615. doi: 10.1177/1534735420986615. PMID: 33870744; PMCID: PMC8056559. Access online here.
  4. Maunsell R, et al. Nutritional care in colorectal cancer-what is the state of play? Colorectal Dis. 2021 Oct 4. doi: 10.1111/codi.15933. Epub ahead of print. PMID: 34605160. Access online here.
  5. Zhou C, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021 Oct 14:e214761. doi: 10.1001/jamaoncol.2021.4761. Epub ahead of print. PMID: 34647988; PMCID: PMC8517885. Access online here.
  6. Li FG, et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. JAMA. 2021 Oct 12;326(14):1381-1389. doi: 10.1001/jama.2021.14892. PMID: 34636862; PMCID: PMC8511979. Access online here.

Amazing Articles of the Week:

Merali Z, et al. Gender-based differences in physician payments within the fee-for-service system in Ontario: a retrospective, cross-sectional study. CMAJ. 2021 Oct 18;193(41):E1584-E1591. doi: 10.1503/cmaj.210437. PMID: 34663601; PMCID: PMC8547248. Access online here.

World’s Best Specialized Hospitals 2021. Newsweek. Tue, Nov 02, 2021.Access online here.

The Paper That Changed My Practice:

Henricks LM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. PMID: 30348537. Access online here.

Other Episodes Mentioned:

The OJC Meets Matt Katz and Andrew Parsonson: Oncology Ontology and Twitter Hashtags

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education. You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology. You can find Hans on Twitter here: @HPrenen


Associate Professor Craig Underhill

Craig Underhill

Associate Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program. You can find Craig on Twitter here: @CraigUnderhill 

Mark Nalder:

Mark Nalder

Dr Mark Nalder is a Medical Oncologist and early career researcher. He is currently the Clinical Research Fellow at Royal Brisbane and Women’s Hospital and is the Queensland committee representative of the Young Oncologists Group of Australia (YOGA).  His current research interests include precision medicine, pharmacogenetics and real-world outcomes. He is currently undertaking a PhD at the University of Queensland, investigating the real-world outcomes of patients treated with immunotherapy-based regimens in Queensland.

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Mark Nalder and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.